Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis.

Schultze-Florey CR, Peczynski C, de Marino I, Polge E, Socié G, Blaise D, Beelen D, Franke GN, Kröger N, Stelljes M, Afanasyev B, Potter V, Gerbitz A, Schetelig J, Peric Z, Schoemans H, Koenecke C, Basak GW; EBMT Transplant Complications Working Party (TCWP).

Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0738-3. [Epub ahead of print] No abstract available.

PMID:
31695171
2.

Defining the layers of a sensory cilium with STORM and cryoelectron nanoscopy.

Robichaux MA, Potter VL, Zhang Z, He F, Liu J, Schmid MF, Wensel TG.

Proc Natl Acad Sci U S A. 2019 Nov 5. pii: 201902003. doi: 10.1073/pnas.1902003116. [Epub ahead of print]

PMID:
31690665
3.

Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years.

Sheth VS, Potter V, Gandhi SA, Kulasekararaj AG, de Lavallade H, Muus P, Pagliuca A, Rice CFM, Mehra V, Grimaldi F, Inam S, Barber LD, Mufti GJ, Marsh JC.

Blood Adv. 2019 Oct 22;3(20):3070-3079. doi: 10.1182/bloodadvances.2019000480.

PMID:
31648330
4.

Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.

Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Oct 23. doi: 10.1038/s41409-019-0720-0. [Epub ahead of print]

PMID:
31645668
5.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.

Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A.

Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16185. [Epub ahead of print]

PMID:
31612473
6.

Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI).

Feliu J, Potter V, Grimaldi F, Clay J, Floro L, Saha C, Barber L, Orti G, Alnagar AA, Garcia-Muñoz R, Kenyon M, Krishnamurthy P, de Lavallade H, Raj K, McLornan D, Pagliuca A, Mufti GJ.

Bone Marrow Transplant. 2019 Sep 26. doi: 10.1038/s41409-019-0695-x. [Epub ahead of print]

PMID:
31558789
7.

Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT.

Br J Haematol. 2019 Oct;187(1):e20-e24. doi: 10.1111/bjh.16136. Epub 2019 Aug 8. No abstract available.

PMID:
31396948
8.

Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience.

Sheth V, Kennedy V, de Lavallade H, Mclornan D, Potter V, Engelhardt BG, Savani B, Chinratanalab W, Goodman S, Greer J, Kassim A, York S, Kenyon M, Gandhi S, Kulasekararaj A, Marsh J, Mufti G, Pagliuca A, Jagasia M, Raj K.

Front Oncol. 2019 Jul 10;9:623. doi: 10.3389/fonc.2019.00623. eCollection 2019.

9.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Jul 5. pii: S1083-8791(19)30418-5. doi: 10.1016/j.bbmt.2019.06.034. [Epub ahead of print]

PMID:
31284069
10.

A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study.

Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, Shaw BE, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE.

Biol Blood Marrow Transplant. 2019 Aug;25(8):e270-e271. doi: 10.1016/j.bbmt.2019.06.005. Epub 2019 Jun 11. No abstract available.

PMID:
31195138
11.

Remission of inflammatory bowel disease in Glucose-6-Phosphatase 3 deficiency by allogeneic haematopoietic stem cell transplantation.

Bolton C, Burch N, Morgan J, Harrison B, Pandey S, Pagnamenta AT, Taylor JC, Taylor JM, Marsh JCW, Potter V, Travis S, Uhlig HH; Oxford IBD cohort investigators.

J Crohns Colitis. 2019 Jun 3. pii: jjz112. doi: 10.1093/ecco-jcc/jjz112. [Epub ahead of print]

PMID:
31157858
12.

Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.

Mehra V, Rhone E, Widya S, Zuckerman M, Potter V, Raj K, Kulasekararaj A, McLornan D, de Lavallade H, Benson-Quarm N, Lim C, Ware S, Sudhanva M, Malik O, Nicholas R, Muraro PA, Marsh J, Mufti GJ, Silber E, Pagliuca A, Kazmi MA.

Clin Infect Dis. 2019 Oct 30;69(10):1757-1763. doi: 10.1093/cid/ciz047.

PMID:
30980715
13.

Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study.

Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, Shaw BE, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE.

Biol Blood Marrow Transplant. 2019 Mar;25(3):443-450. doi: 10.1016/j.bbmt.2018.12.768.

14.

Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.

Fattizzo B, Kulasekararaj AG, Hill A, Benson-Quarm N, Griffin M, Munir T, Arnold L, Riley K, Ireland R, De Lavallade H, Potter V, Consonni D, Hillmen P, Mufti GJ, Barcellini W, Marsh JCW.

Haematologica. 2019 Nov;104(11):e494-e496. doi: 10.3324/haematol.2019.216374. Epub 2019 Mar 19. No abstract available.

15.

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.

Kröger N, Eikema DJ, Köster L, Beelen D, de Wreede LC, Finke J, Koenecke C, Niederwieser D, Bornhäuser M, Schoenland S, Potter V, Wolschke C, Maertens J, Theobald M, Kobbe G, Itälä-Remes M, Wulf G, Kahls P, Forcade E, Greinix H, Masszi T, Yakoub-Agha I, Chalandon Y, Robin M; Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation.

Br J Haematol. 2019 May;185(4):725-732. doi: 10.1111/bjh.15819. Epub 2019 Feb 28.

PMID:
30820933
16.

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.

Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F.

Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13.

17.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2019 Mar;25(3):488-495. doi: 10.1016/j.bbmt.2018.08.029. Epub 2018 Sep 5.

PMID:
30194027
18.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis.

Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon MJP, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N.

Biol Blood Marrow Transplant. 2019 Jan;25(1):114-120. doi: 10.1016/j.bbmt.2018.08.026. Epub 2018 Aug 30.

PMID:
30172776
19.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:310-316. doi: 10.1016/j.lungcan.2018.07.042. Epub 2018 Aug 10.

20.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007. Epub 2018 Jun 9.

21.

Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.

Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, McLornan D, Peffault de Latour R, Potter V, Kulasekararaj A, Sicre de Fontbrune F, Pagliuca A, Yakoub-Agha I, Socié G, Mufti GJ.

Eur J Haematol. 2018 Oct;101(4):466-474. doi: 10.1111/ejh.13085.

PMID:
29714032
22.

Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation.

Tedjaseputra A, McLornan D, McCormick J, Raj K, de Lavallade H, Potter V, Kenyon M, Pagliuca A, Marsh J, Mufti G.

Intern Med J. 2018 Apr;48(4):481-483. doi: 10.1111/imj.13762. No abstract available.

PMID:
29623981
23.

Composite biomarker panel for prediction of severity and diagnosis of acute GVHD with T-cell-depleted allogeneic stem cell transplants-single centre pilot study.

Min SS, Mehra V, Clay J, Cross GF, Douiri A, Dew T, Basu TN, Potter V, Ceesay MM, Pagliuca A, Sherwood RA, Vincent RP.

J Clin Pathol. 2017 Oct;70(10):886-890. doi: 10.1136/jclinpath-2017-204399. Epub 2017 Apr 27.

PMID:
28450387
24.

Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study.

Awan S, Crosby V, Potter V, Hennig I, Baldwin D, Ndlovu M, Paradine S, Wilcock A.

Lung Cancer. 2017 Feb;104:75-78. doi: 10.1016/j.lungcan.2016.12.010. Epub 2016 Dec 21.

PMID:
28213005
25.

Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study.

Crosby V, D'Souza C, Bristow C, Proffitt A, Hussain A, Potter V, Hennig I, O'Connor R, Baracos V, Wilcock A.

Support Care Cancer. 2017 Apr;25(4):1257-1261. doi: 10.1007/s00520-016-3518-2. Epub 2016 Dec 8.

PMID:
27933464
26.

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.

Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R, Sen M, Best S, Lea N, Rice C, Pagliuca A, Mufti GJ, Marsh JCW, Barber LD.

Biol Blood Marrow Transplant. 2017 Feb;23(2):293-299. doi: 10.1016/j.bbmt.2016.11.003. Epub 2016 Nov 2.

27.

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.

Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C.

J Thorac Oncol. 2016 Sep;11(9):1511-21. doi: 10.1016/j.jtho.2016.05.028. Epub 2016 Jun 11.

28.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.

Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, Craddock C, Lenhoff S, Russell NH, Fegueux N, Socié G, Bruno B, Meijer E, Mufti GJ, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1615-1620. doi: 10.1016/j.bbmt.2016.05.026. Epub 2016 Jun 3.

29.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.

Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF.

J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.

30.

Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.

Lal R, Hillerdal GN, Shah RN, Crosse B, Thompson J, Nicolson M, Vikström A, Potter VA, Visseren-Grul C, Lorenzo M, D'yachkova Y, Bourayou N, Summers YJ.

Lung Cancer. 2015 Aug;89(2):154-60. doi: 10.1016/j.lungcan.2015.05.003. Epub 2015 May 12.

PMID:
26101013
31.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

Hickish T, Cassidy J, Propper D, Chau I, Falk S, Ford H, Iveson T, Braun M, Potter V, Macpherson IR, Finnigan H, Lee C, Jones H, Harrison M.

Eur J Cancer. 2014 Dec;50(18):3136-44. doi: 10.1016/j.ejca.2014.08.008. Epub 2014 Oct 28.

PMID:
25441408
32.

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A.

Biol Blood Marrow Transplant. 2015 Jan;21(1):60-6. doi: 10.1016/j.bbmt.2014.09.009. Epub 2014 Sep 28.

33.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, de Lavallade H, Kenyon M, Pagliuca A, Mufti GJ, Marsh JC.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1711-6. doi: 10.1016/j.bbmt.2014.06.028. Epub 2014 Jul 10.

34.

Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.

Noriega V, Kaur H, Devereux S, Byrne J, Marcus R, Haynes A, Yallop D, McMillan A, Ingram W, Khan A, Kenyon M, Potter V, Russell N, Mufti GJ, Pagliuca A.

Leuk Res. 2014 Jul;38(7):737-43. doi: 10.1016/j.leukres.2014.03.005. Epub 2014 Mar 18.

PMID:
24787231
35.

Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.

Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P.

Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5. doi: 10.1016/j.bbmt.2014.03.003. Epub 2014 Mar 18.

36.

Treatment decisions and survival for people with small-cell lung cancer.

Powell HA, Tata LJ, Baldwin DR, Potter VA, Stanley RA, Khakwani A, Hubbard RB.

Br J Cancer. 2014 Feb 18;110(4):908-15. doi: 10.1038/bjc.2013.812. Epub 2014 Jan 7.

37.

Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8.

38.

Haematopoietic stem cell transplantation for acquired aplastic anaemia.

Young ME, Potter V, Kulasekararaj AG, Mufti GJ, Marsh JC.

Curr Opin Hematol. 2013 Nov;20(6):515-20. doi: 10.1097/MOH.0b013e328365af83. Review.

PMID:
24104412
39.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

40.

Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.

Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA, O'Dwyer PJ.

Clin Cancer Res. 2013 May 1;19(9):2541-50. doi: 10.1158/1078-0432.CCR-13-0107. Epub 2013 Mar 26.

41.

A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.

Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA.

Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.

42.

High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E.

Bhattacharjee PS, Huq TS, Potter V, Young A, Davenport IR, Graves R, Mandal TK, Clement C, McFerrin HE, Muniruzzaman S, Ireland SK, Hill JM.

PLoS One. 2012;7(12):e52152. doi: 10.1371/journal.pone.0052152. Epub 2012 Dec 19.

43.

Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.

Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21.

44.

Myelodysplastic syndromes: who and when in the course of disease to transplant.

Mufti GJ, Potter V.

Hematology Am Soc Hematol Educ Program. 2012;2012:49-55. doi: 10.1182/asheducation-2012.1.49. Review.

PMID:
23233560
45.

Ability to regulate emotion is predicted by depressive symptoms and cognitive function in a cardiac sample.

Spitznagel MB, Potter V, Miller LA, Roberts Miller AN, Hughes J, Rosneck J, Gunstad J.

J Cardiovasc Nurs. 2013 Sep-Oct;28(5):453-9. doi: 10.1097/JCN.0b013e318256be99.

PMID:
22728775
46.

Identifying patients at risk of severe Clostridium difficile-associated disease.

Potter VA, Aravinthan A.

Br J Hosp Med (Lond). 2012 May;73(5):265-70. Review.

PMID:
22585325
47.

Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.

Nagi W, Lim ZY, Krishnamurthy P, Potter V, Tindell V, Reiff-Zall L, Abdullah A, Lea N, Kenyon M, Marsh J, Ho AY, Mufti GJ, Pagliuca A.

Leuk Res. 2011 Aug;35(8):998-1000. doi: 10.1016/j.leukres.2011.02.012. Epub 2011 Jun 24.

PMID:
21704371
48.

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, Potter V, Koh MB, Islam MS, Russell N, Marks DI, Mufti GJ, Pagliuca A.

Blood. 2011 Aug 25;118(8):2351-7. doi: 10.1182/blood-2010-12-327536. Epub 2011 Apr 25.

PMID:
21518925
49.

The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.

Li-Wan-Po A, Farndon PA, Kobayashi S, Mitsudomi T, Potter VA.

Ann Pharmacother. 2011 Feb;45(2):263-75. doi: 10.1345/aph.1P496. Review.

PMID:
21304034
50.

Structured exercise does not stabilize cognitive function in individuals with mild cognitive impairment residing in a structured living facility.

Miller LA, Spitznagel MB, Busko S, Potter V, Juvancic-Heltzel J, Istenes N, Glickman E, Gunstad J.

Int J Neurosci. 2011 Apr;121(4):218-23. doi: 10.3109/00207454.2010.546537. Epub 2011 Jan 19.

Supplemental Content

Loading ...
Support Center